ATAI Key Statistics, Chart & Performance
The current stock price of ATAI is 3.87 USD. In the past month the price decreased by -27.66%. In the past year, price increased by 148.08%.
ATAI Latest News, Press Relases and Analysis
ATAI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.57 | 988.98B | ||
| JNJ | JOHNSON & JOHNSON | 19.79 | 494.92B | ||
| MRK | MERCK & CO. INC. | 11.47 | 250.76B | ||
| PFE | PFIZER INC | 7.86 | 143.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.36 | 98.22B | ||
| ZTS | ZOETIS INC | 19.63 | 54.84B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.82B | ||
| VTRS | VIATRIS INC | 4.6 | 12.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.43 | 11.17B | ||
| CORT | CORCEPT THERAPEUTICS INC | 91.77 | 8.50B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.16B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.26B |
Related stock screener links
About ATAI
Company Profile
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
Company Info
ATAI BECKLEY NV
Prof. J.H.Bavincklaan 7
Amstelveen NOORD-HOLLAND 100022 NL
CEO: Florian Brand
Employees: 54
Phone: 31207932536
ATAI BECKLEY NV / ATAI FAQ
What does ATAI do?
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
What is the current price of ATAI stock?
The current stock price of ATAI is 3.87 USD. The price increased by 0.78% in the last trading session.
Does ATAI stock pay dividends?
ATAI does not pay a dividend.
How is the ChartMill rating for ATAI BECKLEY NV?
ATAI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting ATAI stock to perform?
17 analysts have analysed ATAI and the average price target is 12.35 USD. This implies a price increase of 219.21% is expected in the next year compared to the current price of 3.87.
How is the valuation of ATAI BECKLEY NV (ATAI) based on its PE ratio?
ATAI BECKLEY NV (ATAI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.81).
Can you provide the growth outlook for ATAI BECKLEY NV?
The Revenue of ATAI BECKLEY NV (ATAI) is expected to grow by 355.42% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ATAI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ATAI. When comparing the yearly performance of all stocks, ATAI is one of the better performing stocks in the market, outperforming 95.53% of all stocks.
ATAI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ATAI. While ATAI has a great health rating, there are worries on its profitability.
ATAI Financial Highlights
Over the last trailing twelve months ATAI reported a non-GAAP Earnings per Share(EPS) of -0.81.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -78.89% | ||
| ROE | -103.85% | ||
| Debt/Equity | 0 |
ATAI Forecast & Estimates
17 analysts have analysed ATAI and the average price target is 12.35 USD. This implies a price increase of 219.21% is expected in the next year compared to the current price of 3.87.
For the next year, analysts expect an EPS growth of 45.22% and a revenue growth 355.42% for ATAI